Business Description
ProQR Therapeutics NV
ISIN : NL0010872495
Compare
Compare
Traded in other countries / regions
PRQR.USA0PQ.GermanyPRQR.Mexico IPO Date
2014-09-18Description
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.03 | |||||
| Equity-to-Asset | 0.3 | |||||
| Debt-to-Equity | 0.48 | |||||
| Debt-to-EBITDA | -0.83 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -2.99 | |||||
| Beneish M-Score | -4.99 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 31.8 | |||||
| 3-Year EPS without NRI Growth Rate | 26 | |||||
| 3-Year Book Growth Rate | -26.2 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.8 | |||||
| 9-Day RSI | 41.83 | |||||
| 14-Day RSI | 43.34 | |||||
| 6-1 Month Momentum % | 81.68 | |||||
| 12-1 Month Momentum % | 3.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.54 | |||||
| Quick Ratio | 3.54 | |||||
| Cash Ratio | 3.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17.5 | |||||
| Shareholder Yield % | 13.18 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -532.75 | |||||
| Net Margin % | -429.75 | |||||
| FCF Margin % | 303.19 | |||||
| ROE % | -53.17 | |||||
| ROA % | -18.63 | |||||
| ROIC % | -73.97 | |||||
| ROC (Joel Greenblatt) % | -161.6 | |||||
| ROCE % | -21 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Price-to-Owner-Earnings | 6.55 | |||||
| PS Ratio | 22.23 | |||||
| PB Ratio | 3.61 | |||||
| Price-to-Tangible-Book | 3.61 | |||||
| Price-to-Free-Cash-Flow | 7.32 | |||||
| Price-to-Operating-Cash-Flow | 6.78 | |||||
| EV-to-EBIT | -1.99 | |||||
| EV-to-EBITDA | -2.2 | |||||
| EV-to-Revenue | 8.08 | |||||
| EV-to-Forward-Revenue | 7.6 | |||||
| EV-to-FCF | 2.67 | |||||
| Price-to-Net-Current-Asset-Value | 6.12 | |||||
| Price-to-Net-Cash | 6.73 | |||||
| Earnings Yield (Greenblatt) % | -50.25 | |||||
| FCF Yield % | 13.01 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PRQR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ProQR Therapeutics NV Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 7.05 | ||
| EPS (TTM) ($) | -0.377 | ||
| Beta | -0.25 | ||
| Volatility % | 60.21 | ||
| 14-Day RSI | 43.34 | ||
| 14-Day ATR ($) | 0.17528 | ||
| 20-Day SMA ($) | 2.166995 | ||
| 12-1 Month Momentum % | 3.48 | ||
| 52-Week Range ($) | 1.11 - 3.29 | ||
| Shares Outstanding (Mil) | 81.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ProQR Therapeutics NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ProQR Therapeutics NV Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
ProQR Therapeutics NV Frequently Asked Questions
What is ProQR Therapeutics NV(PRQR)'s stock price today?
The current price of PRQR is $2.01. The 52 week high of PRQR is $3.29 and 52 week low is $1.11.
When is next earnings date of ProQR Therapeutics NV(PRQR)?
The next earnings date of ProQR Therapeutics NV(PRQR) is 2024-05-16 Est..
Does ProQR Therapeutics NV(PRQR) pay dividends? If so, how much?
ProQR Therapeutics NV(PRQR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers